[go: up one dir, main page]

AU1930900A - Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith - Google Patents

Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith

Info

Publication number
AU1930900A
AU1930900A AU19309/00A AU1930900A AU1930900A AU 1930900 A AU1930900 A AU 1930900A AU 19309/00 A AU19309/00 A AU 19309/00A AU 1930900 A AU1930900 A AU 1930900A AU 1930900 A AU1930900 A AU 1930900A
Authority
AU
Australia
Prior art keywords
therapiesassociated
immunity
therewith
protease inhibitors
cellular pathways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19309/00A
Inventor
Joseph L Bryant
Robert C. Gallo
Frank F. Weichold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Maryland Biotechnology Institute
Original Assignee
The University of Maryland Biotechnology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Maryland Biotechnology Institute filed Critical The University of Maryland Biotechnology Institute
Publication of AU1930900A publication Critical patent/AU1930900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU19309/00A 1998-12-04 1999-12-03 Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith Abandoned AU1930900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11089398P 1998-12-04 1998-12-04
US60110893 1998-12-04
PCT/US1999/028548 WO2000033654A1 (en) 1998-12-04 1999-12-03 Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith

Publications (1)

Publication Number Publication Date
AU1930900A true AU1930900A (en) 2000-06-26

Family

ID=22335504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19309/00A Abandoned AU1930900A (en) 1998-12-04 1999-12-03 Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith

Country Status (2)

Country Link
AU (1) AU1930900A (en)
WO (1) WO2000033654A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
ATE338564T1 (en) 2000-10-12 2006-09-15 Viromics Gmbh PROTEASOME INHIBITORS FOR THE TREATMENT OF HEPATITIS VIRUS INFECTIONS
DE10051716A1 (en) * 2000-10-12 2002-04-25 Ulrich Schubert Composition for treating viral infections, especially caused by retro- or hepatitis viruses, comprises proteosome inhibitor that prevents release, maturation or replication
ITRM20010210A1 (en) * 2001-04-18 2002-10-18 Ist Superiore Sanita USE OF HUMAN IMMUNODEFICIENCY VIRUS PROTEASIS INHIBITORS (HIV) IN KAPOSI SARCOMA THERAPY, CANCER AND DISEASES THERAPY
US20030138423A1 (en) * 2001-12-14 2003-07-24 Cedars-Sinai Medical Center Method of treating inflammation with HIV-1 protease inhibitors and their derivatives
WO2003092605A2 (en) * 2002-04-30 2003-11-13 Trustees Of Tufts College Protease inhibitors
US20050171022A1 (en) * 2002-07-03 2005-08-04 Charite-Universitaetsmedizin Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
MXPA05013982A (en) 2003-06-20 2006-05-25 Nereus Pharmaceuticals Inc Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases.
WO2006017346A1 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH A ND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER Treatment of viral infections by means o proteasome inhibitors
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102006008321A1 (en) * 2006-02-17 2007-08-30 Virologik Gmbh Agent for the treatment of infections with influenza viruses
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
FR2970179B1 (en) * 2011-01-11 2013-01-18 Centre Nat Rech Scient MEANS FOR REDUCING OR ERADICATING THE TUMOR POWER OF CANCER AND / OR METASTASIC STEM CELLS
DE102014010220A1 (en) 2014-07-10 2016-01-14 Immunologik Gmbh Agent for the treatment of retroviral infections
DE102014010218A1 (en) 2014-07-10 2016-01-14 Immunologik Gmbh Agent for the treatment of retroviral infections
DE102015201100B4 (en) 2015-01-22 2018-05-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Antiviral agent
WO2016137844A1 (en) * 2015-02-23 2016-09-01 Mayo Foundation For Medical Education And Research Methods and materials for treating human immunodeficiency virus infections
WO2016172194A1 (en) 2015-04-20 2016-10-27 Mayo Foundation For Medical Education And Research Methods and materials for killing hiv infected cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors

Also Published As

Publication number Publication date
WO2000033654A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
AU1930900A (en) Use of protease inhibitors to modulate cellular pathways, immunity and therapiesassociated therewith
AU3972697A (en) Inhibitors of cysteine protease
AU8875398A (en) 1-amino-7-isoquinoline derivatives as serine protease inhibitors
HUP0300385A3 (en) Inhibitors of aspartyl protease
AU4723799A (en) Protease inhibitors
PL328665A1 (en) Inhibitors of serinic protease
AU3622600A (en) Metalloproteinases and methods of use therefor
AU5463099A (en) Inhibitors of redox signaling and methods of using same
AU7139598A (en) Protease inhibitors
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU4092799A (en) Protease inhibitors
AU6536200A (en) Proteases and protease inhibitors
HUP9904165A3 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
AU9624398A (en) Pyrrolopyrrolidine derivatives and their use as serine protease inhibitors
AU9110298A (en) Protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
AU2424499A (en) Heterocyclic amidines as callicrein protease inhibitors
AU1588901A (en) Protease inhibitors
AU2713100A (en) Protease inhibitors
AU4564499A (en) Protease inhibitors
AU1474801A (en) Protease inhibitors
AU9300298A (en) Protease inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU3888200A (en) Protease inhibitors
AU1474601A (en) Protease inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase